Introduction
============

More cancer patients die of lung cancer than of any other cancer.[@b1-cmar-4-347],[@b2-cmar-4-347] Early detection and treatment has shown overall improved outcomes in patients with lung cancer.[@b3-cmar-4-347],[@b4-cmar-4-347] The current standard of care for early stage non-small cell lung cancer (NSCLC) is invasive local control through surgical resection typically by lobectomy.[@b3-cmar-4-347] Significant decrease in pulmonary function after lobectomy has been noted in earlier studies.[@b5-cmar-4-347],[@b6-cmar-4-347] Win et al found that NSCLC patients who underwent lobectomy "suffered a significant reduction of pulmonary reserve" and lost a great deal of lung function and exercise capacity.[@b6-cmar-4-347] Functional lung status was measured using pulmonary function tests (PFT) in these studies.

For patients with stage 1 NSCLC who are inoperable or do not want to undergo surgery, external beam radiotherapy is the next best treatment as per the current standards. However, conventional radiotherapy has a high local failure rate of 6.4%--70% and has an estimated five-year overall survival rate of 21% ± 8%.[@b7-cmar-4-347] Symptomatic radiation pneumonitis is present in 5% to 30% of patients receiving radiotherapy for thoracic malignancies. In addition, 50% to 90% of patients experience declines in pulmonary function test measurements.[@b8-cmar-4-347]--[@b13-cmar-4-347] The decrease in lung function in both surgical and radiotherapy therapy patients is very significant considering that most lung cancer patients already have poor lung function as most of them also have a history of smoking. Reducing the morbidity of treatment could possibly improve the quality of life in the survivors. There have been significant advances in treatment technology in recent years that will reduce damage to healthy lung tissue during NSCLC treatment by surgery or radiotherapy. One such treatment is CyberKnife.

CyberKnife is a noninvasive, highly specific radiological method of treating cancer tissue with relative preservation of the surrounding healthy tissues. It has been approved and used to treat early stage NSCLC with excellent results. CyberKnife has the unique ability to track dynamic targets that move with breathing. Thus it limits radiation exposure and damage to normal tissue.[@b14-cmar-4-347] Despite its great promise in treatment of lung cancer, no previous studies have specifically documented CyberKnife's effect on pulmonary function studies. This study aims to confirm that in treatment of lung cancer, especially early stage, CyberKnife preserves lung function better than the current standard of care. The objective is to compare pre- and post-PFTs of patients treated with CyberKnife for lung cancer and ascertain how much lung function is preserved after the treatment.

Methods and materials
=====================

This is an Internal Review Board-approved, retrospective, observational cohort study of patients diagnosed with lung cancer to determine if there are differences in lung function before and after radiosurgery using CyberKnife. Pulmonary function tests were performed on the group before CyberKnife treatment and repeated 3--4 months after treatment.

We included patients diagnosed with primary or metastatic lung cancer who opted for CyberKnife treatment and had pre- and post-treatment pulmonary function tests. We excluded patients who did not fulfill the above criteria.

Abstracted data was entered into a Microsoft Access database and transferred to SPSS statistical software (v 20.0; IBM Corporation, Armonk, NY). Analysis included generation of descriptive statistics to adequately describe the sample. We also conducted paired *t*-tests to determine differences in pulmonary function data pre- and postoperatively (at 3 to 4 months). In addition, we conducted subgroup analysis based on gender, location, and stage of tumor. We compared eleven parameters of pulmonary function tests including: forced vital capacity (FVC), forced expiratory volume in 1 second (FEV~1~), FEV~1~/FVC ratio, forced expiratory flow 25%--75%, forced inspiratory vital capacity, slow vital capacity, inspiratory capacity, expiratory reserve volume, diffusing capacity of the lung for carbon monoxide, diffusion capacity corrected for alveolar volume, and alveolar volume.

Results
=======

Thirty-seven patients were included in the study. The median age of the group was 73 years ([Table 1](#t1-cmar-4-347){ref-type="table"}). Approximately 49% of the subjects were female, while 51% were males. Three patients were given 5000 cGy in five divided fractions and 34 patients received 6000 cGy in five divided fractions. All the patients had smoking history. Stage 1 cancer was documented in 22 patients, stage 2 in two patients, stage 3 in five patients and stage 4 cancer in eight patients. The location of the tumors is mentioned in [Table 1](#t1-cmar-4-347){ref-type="table"}.

Paired *t*-tests indicated that there was no statistical difference between pre-CyberKnife and post-CyberKnife treatment in terms of mean PFTs for the overall group ([Table 2](#t2-cmar-4-347){ref-type="table"}) and for subgroups based on gender and tumor location.

Analysis of subgroups based on stage indicate that stage 4 PFTs were significantly decreased for FVC, but significantly increased for the FEV~1~/FVC ratio, at 3 months compared to zero months ([Figure 1](#f1-cmar-4-347){ref-type="fig"}).

Discussion
==========

CyberKnife treatment has been shown to be very effective for stage 1 NSCLC in multiple studies published in last few years.[@b15-cmar-4-347]--[@b19-cmar-4-347] In our study, we observed that CyberKnife is successful in preserving lung function status as was measured by pulmonary function tests. This observation supports the emerging role of CyberKnife in lung cancer management.

Our results are in line with the conclusions of Stephans et al, who studied Novalis treatment (another stereotactic body radiation therapy) and found no significant differences in PFT pre- and posttreatment.[@b20-cmar-4-347] In Novalis treatment usually an abdominal compression devise is used to limit patients' respiration, increasing patient discomfort. CyberKnife treatment does not need any method to limit breathing because of its tumor-tracking ability. Collins et al reported similar results for FVC and FEV~1~.[@b19-cmar-4-347] They also reported other side effects of CyberKnife treatment being pneumothorax and radiation pneumonitis. They did show a decrease in diffusing capacity of the lung for carbon monoxide at 6 months in the treated patients.[@b19-cmar-4-347] We did not see any such decrease at 3 months. We will continue to collect long-term follow-up data on our patients to determine if any changes in lung function occur longitudinally.

Most of the patients in the study were referred to a radiation oncology department after they were considered not eligible for surgery or the patient opted for radiation treatment. CyberKnife was offered to these patients because of decreased duration of treatment, convenience to the patient, and possibility of decreased damage to normal lung tissue.

The small sample size, nonrandomization, and retrospective nature of our study are certain limitations of our study and interpretation of the results should be made with caution. Prospective randomized trials comparing CyberKnife to conventional radiotherapy, other types of stereotactic body radiation therapies, and surgical treatments could further clarify the role of CyberKnife treatment.

Conclusion
==========

In our study, we observed that CyberKnife was successful in preserving lung functions at 3--4 months, unlike the current standards of care, and also has a better side-effect profile. Compared to other methods of stereotactic body radiotherapy, it is more comfortable, as it does not need any methods or devices to restrict the patient. The CyberKnife has proved to be a safe and effective treatment. Our study is limited by a small sample size and the results should be interpreted with caution. More research is needed in this field.
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###### 

Patient characteristics

  --------------------------------------- ----------
  Age (median) (years)                    73
  Male-n (%)                              19 (51)
  Smoking-n (%)                           37 (100)
  Location                                
   Left upper lobe-n (%)                  13 (35)
   Left lower lobe-n (%)                  4 (11)
   Right upper lobe-n (%)                 7 (20)
   Right medial lobe-n (%)                1 (3)
   Right lower lobe-n (%)                 10 (30)
   Right hilar lymph nodal region-n (%)   2 (5)
  Stage                                   
   Stage I-n (%)                          22 (59)
   Stage II-n (%)                         2 (5)
   Stage III-n (%)                        5 (14)
   Stage IV-n (%)                         8 (22)
  Dose of radiation received              
   5000 cGy-n (%)                         3 (8)
   6000 cGy-n (%)                         34 (92)
  --------------------------------------- ----------

###### 

Comparison of pulmonary function tests pre- and post-CyberKnife treatment

  ----------------------------------------------------------------------------
  Pulmonary function test results\                                     
  Pre-CyberKnife vs 3--4 months post-CyberKnife                        
  ----------------------------------------------- ------- ---- ------- -------
  FVC -- pre                                      76.2    37   21.6    0.346

  FVC -- post                                     74.2    37   19.6    

  FEV~1~ -- pre                                   56.5    37   22.1    0.781

  FEV~1~ -- post                                  56.2    37   21.9    

  FEV~1~/FVC -- pre                               74.6    37   17.9    0.905

  FEV~1~/FVC -- post                              74.8    37   18.0    

  FEF -- pre                                      29.4    37   21.7    0.478

  FEF -- post                                     31.0    37   20.9    

  FIVC -- pre                                     2.1     33   0.7     0.189

  FIVC -- post                                    2.2     33   0.8     

  SVC -- pre                                      75.1    35   17.8    0.383

  SVC -- post                                     76.9    35   17.7    

  IC -- pre                                       74.9    32   17.8    0.267

  IC -- post                                      72.1    32   20.9    

  ERV -- pre                                      106.9   32   146.8   0.668

  ERV -- post                                     112.7   32   92.0    

  DLCO -- pre                                     56.1    33   24.4    0.672

  DLCO -- post                                    54.8    33   19.8    

  DLVA -- pre                                     79.6    32   30.5    0.287

  DLVA -- post                                    90.8    32   53.5    

  VA -- pre                                       71.1    32   19.1    0.299

  VA -- post                                      67.0    32   21.4    
  ----------------------------------------------------------------------------

**Abbreviations:** PFT, pulmonary function test; FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 second; FEF, forced expiratory flow; FIVC, forced inspiratory vital capacity; SVC, slow vital capacity; IC, inspiratory capacity; ERV, expiratory reserve volume; DLCO, diffusing capacity of the lung for carbon monoxide; DLVA, diffusion capacity corrected for alveolar volume; VA, alveolar volume.
